Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate
NCT00755872 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76
Last updated 2011-10-12
Summary
This is a randomized, open-label, multi-center, 4-treatment, 4-period crossover study. Approximately 72 healthy, surgically sterile or postmenopausal subjects will be enrolled and have urine collected over 72 hours following administration of risedronate for all 4 treatment periods).
Conditions
- Bioavailability
Interventions
- DRUG
-
Risedronate
Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
- DRUG
-
Risedronate
Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
- DRUG
-
Risedronate
Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
- DRUG
-
Risedronate
Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
Sponsors & Collaborators
- collaborator INDUSTRY
-
Warner Chilcott
lead INDUSTRY
Principal Investigators
-
William S Aronstein, MD, PhD · Procter and Gamble
Study Design
- Allocation
- RANDOMIZED
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 40 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-11-30
- Primary Completion
- 2008-02-29
- Completion
- 2008-02-29
Countries
- United States
Study Locations
More Related Trials
-
Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fasting Condition
NCT01506050 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting Conditions
NCT01161927 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions
NCT01314352 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Dr. Reddy's Divalproex Sodium Capsules (Sprinkle), 125 mg Under Fasting Conditions
NCT01055938 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fed Condition
NCT01506037 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalency Study of Divalproex Sodium DR Tablets, 500 mg of Dr.Reddy's Under Fasting Conditions
NCT01132170 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants
NCT04718181 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Risperidone Tablet 1 mg Under Fasting Condition
NCT01722201 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Under Fed Conditions
NCT01132196 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fed Conditions
NCT01645423 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Risperidone 1.0 mg Tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fasting Conditions
NCT00939497 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Risperidone Tablet 1 mg Under Fed Condition
NCT01618760 ·Status: COMPLETED ·Phase: PHASE1
-
A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fed Conditions
NCT01499771 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fasting Conditions
NCT01645449 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability Study
NCT02159313 ·Status: COMPLETED ·Phase: PHASE1
-
Comparative Bioavailability Study of Lisinopril Tablets, 10 mg
NCT01375244 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Non-Fasting Conditions
NCT01372358 ·Status: COMPLETED ·Phase: PHASE1
-
Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
NCT06233227 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Bioequivalence Study of Risperidone 1 mg Tablets of Torrent Pharmaceuticals Limited, India and Risperdal® (Risperidone) 1 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fed Conditions
NCT00939926 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.
NCT00557128 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Desloratadine and Pseudoephedrine Extended-release Tablets Under Fed Conditions
NCT01506791 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of 10 mg Amlodipine Besylate/ 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Non-fasting (Fed) Conditions
NCT01155908 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fasting Conditions
NCT01155947 ·Status: COMPLETED ·Phase: PHASE1
-
A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fasting Conditions.
NCT01499758 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition
NCT01159158 ·Status: COMPLETED ·Phase: PHASE1